

- in returning war veterans, 152e-9  
treatment of, 832-833, 832t
- Soft tissue sarcoma, 119e-1**  
classification of, 119e-1  
deaths from, 470t  
diagnosis of, 119e-1-2  
epidemiology of, 119e-1  
genetic considerations in, 119e-1  
incidence of, 119e-1  
metastatic, 119e-2  
prognosis of, 119e-2  
staging of, 119e-2, 119e-2t  
treatment of, 103e-19, 119e-2
- SOI (severity-of-illness) scoring systems, 1729, 1730t**
- SOJIA (systemic onset juvenile idiopathic arthritis), 372e-8t**
- Solar elastosis, 386, 387**
- Solar purpura, 367**
- Solar radiation, 385**
- Solar urticaria, 363, 363t, 2118**
- Solid organ transplantation. *See also* Transplant recipient**  
brain injury after, 463e-3  
heart. *See* Cardiac transplantation  
infections after, 923-924, 924t, 925t  
kidney. *See* Kidney transplantation  
liver. *See* Liver transplantation  
lung. *See* Lung transplantation
- Solifenacin, 81**
- Solitary rectal ulcer syndrome, 277, 1957**
- Soluble defense collagens (collectins), 145e-5**
- Solute diuresis, 295**
- Somali famine, 151e-3**
- Soman. *See* Nerve agents**
- Somatic hypermutation, 372e-20, 372e-21**
- Somatic mosaicism, 439**
- Somatic mutations**  
cancer development and, 101e-1, 101e-1f, 440  
in mitochondrial DNA, 439
- Somatic symptom disorder, 2718**
- Somatization, 254**
- Somatosensory cortex, 88, 89f, 176f**
- Somatosensory evoked potentials (SSEPs), 442e-3-4, 1781**
- Somatosensory pathways, 159f**
- Somatostatin**  
actions of, 401e-2, 570, 1912  
half-life of, 400e-2  
structure of, 566f  
synthesis of, 401e-3
- Somatostatin analogues**  
for acromegaly, 2270f, 2271  
adverse effects of, 574, 1853, 2271  
for carcinoid syndrome, 272, 567  
for Cushing's syndrome, 2272-2273  
for nausea and vomiting, 260t  
for polycystic kidney disease, 1853  
for TSH-secreting adenomas, 2274  
for VIPoma, 571
- Somatostatinoma, 269, 559t, 561, 570**
- Somatostatin receptor scintigraphy (SRS), 571-572, 572f**
- Somatotropin, 2258t**
- Somnambulation, 192**
- Sorafenib**  
action and targets of, 101e-8, 102e-3, 102e-5t, 102e-17, 103e-16f, 103e-18t, 103e-19  
adverse effects of, 103e-18t, 103e-19, 103e-26, 380, 381f, 551  
for cholangiocarcinoma, 553  
for hepatocellular carcinoma, 102e-3, 102e-17, 550, 551, 551t, 552  
for renal cell carcinoma, 102e-3, 102e-5t, 102e-17, 579  
for thyroid cancer, 2307
- Sorbitol, 1970t, 2743**
- Sotalol**  
action of, 273e-6t  
adverse effects of, 1480t, 1498  
for arrhythmias, 1480t  
for atrial fibrillation, 1489  
for atrial flutter, 1485  
dosage in kidney disease, 37
- dosage monitoring, 36**
- drug interactions of, 43**
- for focal atrial tachycardia, 1479  
overdosage/poisoning with, 473e-9t  
pharmacology of, 1480t  
for ventricular arrhythmias, 1498
- Sour taste sensation, 212**
- Southeast Asia ovalocytosis, 653, 653t**
- Southern tick-associated rash illness (Master's disease), 129t, 134, 1152**
- Sowdah, 1420**
- Sox2 gene, 454, 455**
- SOX3 gene mutations, 2325t**
- SOX9 gene, 2349, 2351f**
- SOX9 gene mutations**  
in disorders of testis development, 2353, 2354t  
in testicular/ovotesticular disorders of sex development, 2355, 2356t
- SOX-10, 372e-24t**
- SOX-10 gene mutations, 359**
- SOX18 gene mutations, 1654**
- Sp110 deficiency, 375e-2, 2110**
- SPARC, 554**
- Sparganosis, 1435**
- Spasmodic dysphonia, 2620**
- Spasms**  
hemifacial, 2648  
in MS, 2663, 2672  
muscle, 462e-2-3  
in tetanus, 985, 986
- Spasticity, 154, 163, 2660**
- Spastin gene, 2634t, 2636**
- Spatial orientation, 180-182, 180f**
- Specialized nutritional support, 98e-1**  
approach to the patient, 98e-1-4  
benefits of, 98e-3-4  
decision-making for implementation of, 98e-2f
- design of regimens for**  
amino acids, 98e-5  
energy requirements, 98e-4-5  
fluid requirements, 98e-4, 98e-4t  
minerals and vitamins, 98e-5, 98e-5t, 98e-6t  
monomeric formulas, 98e-5  
proteins, 98e-5
- disease-specific, 98e-4**
- enteral. *See* Enteral nutrition**
- home, 98e-4**
- hyperglycemia and, 98e-4**
- indications for, 98e-1-3, 98e-2f**
- parenteral. *See* Parenteral nutrition**
- risks of, 98e-3-4**
- Specific granule deficiency, 419, 419t**
- Specificity**  
analytical, 480e-2  
in immune response, 372e-2  
of tests, 21, 22, 479, 479t
- SPECT (single photon emission computed tomography)**  
for myocardial perfusion imaging. *See* Myocardial perfusion imaging
- in parathyroid surgery, 2474**
- radiopharmaceuticals for, 270e-3, 270e-3t**
- Spectinomycin**  
action of, 930  
for gonococcal infections, 1008, 1009t  
resistance to, 1004-1005
- Speech**  
assessment of, 37e-1v, 2537  
spontaneous, 177
- Speech audiometry, 222**
- Speech reception threshold, 222**
- Sperm, mutations in, 433**
- Spermatogenesis**  
abnormalities of, genetic considerations in, 433, 437  
process of, 2358f, 2359-2360  
radiation-induced effects on, 623
- Spermatogonial stem cells, 453t, 454**
- Sperm banking, 103e-25, 592, 623**
- Spermidine, 94e-6f, 94e-7**
- S-phase analysis, in breast cancer, 528**
- Spherocytosis, 81e-3f, 281**
- Spherules, 1335, 1335f**
- Sphincter of Oddi, 2076, 2082-2083**
- Sphincteroplasty, 1976**
- Sphincterotomy, endoscopic, 1881, 1884f**
- Spider angioma, 286, 1992, 2058, 2059f**
- Spider bites, 365, 2747**
- Spina bifida occulta, 118**
- Spinal accessory nerve, 2538**
- Spinal anesthesia, 54**
- Spinal angiography, 440e-10-11**
- Spinal cord**  
age-related changes in, 76  
anatomy of, 2650-2651, 2652f  
compression of. *See* Spinal cord compression  
disorders of. *See* Spinal cord disease/injury  
pain mechanisms of, 88, 89f
- Spinal cord compression**  
in hematomyelia, 2655
- IgG4-related, 391e-1t**
- neoplastic**  
clinical features of, 1790-1791, 2653  
diagnosis of, 1791, 1791f, 2653, 2653f  
in intradural mass lesions, 2654, 2654f  
in lung cancer, 513  
metastatic, 1790, 2653  
pathogenesis of, 2653  
in primary intramedullary tumors, 2654, 2654f  
treatment of, 1791-1792, 1791f, 2653-2654  
in spinal epidural abscess, 780t, 784, 2654-2655f
- in spinal epidural hematoma, 2655**
- Spinal cord disease/injury, 2650**  
acute, 2653  
anatomic considerations in, 2650-2651, 2651t, 2652f  
approach to the patient, 2650-2653, 2651t  
autonomic dysfunction in, 2641-2642, 2660  
cervical. *See* Cervical spine  
compressive. *See* Spinal cord compression  
constipation in, 274  
erectile dysfunction in, 326  
in HIV infection, 1266-1267  
infarction, 441e-25f, 2655-2656  
infectious. *See* Meningitis  
level of lesion in, 2540t, 2651-2652, 2651t  
myelopathies. *See* Myelopathy  
neurogenic shock in, 1750  
paraneoplastic syndromes, 618  
patterns of, 2653  
prognosis of, 2660t  
radiation-induced, 103e-4, 622  
referred abdominal pain from, 105  
remyelination after, 90e-3  
sensory abnormalities in, 161  
stem cell therapy for, 90e-3  
subacute, 2653  
treatment of, 2659-2660  
vascular malformations, 2657, 2658f
- Spinal epidural abscess**  
clinical features of, 117, 784, 2654  
diagnosis of, 2654, 2655f  
etiology of, 784, 2654  
risk factors for, 2654  
treatment of, 780t, 2655
- Spinal epidural hematoma, 2655**
- Spinal fusion, 120**
- Spinal manipulative therapies, 14e-1t, 14e-2-3, 119**
- Spinal muscle atrophy (SMA), 2631, 2634t, 2636**
- Spinal osteomyelitis. *See* Osteomyelitis, vertebral**
- Spinal stenosis, 115-116, 116f**
- Spindle cell tumor, 372**
- Spine**  
anatomy of, 111, 112f  
cervical. *See* Cervical spine  
lumbar  
congenital anomalies of, 118  
disk disease in, 113f, 114-115, 115f  
disk replacement in, 120  
fusion surgery in, 120  
pain referred to, 118  
pain sensitive structures in, 111  
sacral, 118
- SPINK1 gene mutations, 2092, 2099, 2101**